137 related articles for article (PubMed ID: 31734798)
41. Adherence trajectories in oral therapy for chronic myeloid leukemia: Overview of a research protocol.
Yeager KA; Waldrop-Valverde D; Paul S; Bruner DW; Klisovic R; Burns E; Mason TA; Patel N; Jennings BM
Res Nurs Health; 2020 Sep; 43(5):443-452. PubMed ID: 32866350
[TBL] [Abstract][Full Text] [Related]
42. Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study.
Tan BK; Tan SB; Chen LC; Chang KM; Chua SS; Balashanker S; Kamarul Jaman HNB; Edmund SC; Bee PC
Patient Prefer Adherence; 2017; 11():1027-1034. PubMed ID: 28652712
[TBL] [Abstract][Full Text] [Related]
43. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.
Cerveira N; Loureiro B; Bizarro S; Correia C; Torres L; Lisboa S; Vieira J; Santos R; Pereira D; Moreira C; Chacim S; Domingues N; Espírito-Santo A; Oliveira I; Moreira I; Viterbo L; Martins Â; Teixeira MR; Mariz JM
BMC Cancer; 2018 Dec; 18(1):1245. PubMed ID: 30541488
[TBL] [Abstract][Full Text] [Related]
44. Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors.
Hefner J; Csef EJ; Kunzmann V
Oncol Nurs Forum; 2017 Nov; 44(6):E232-E240. PubMed ID: 29052661
[TBL] [Abstract][Full Text] [Related]
45. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
46. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
[TBL] [Abstract][Full Text] [Related]
47. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).
Möbius S; Schenk T; Himsel D; Maier J; Franke GN; Saussele S; Pott C; Andrikovics H; Meggyesi N; Machova-Polakova K; Zizkova H; Jurcek T; Mesanovic S; Zadro R; Gottardi E; Haenig J; Schuld P; Cross NCP; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1645-1650. PubMed ID: 30941573
[TBL] [Abstract][Full Text] [Related]
48. Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.
Ishikawa M; Iriyama N; Tokuhira M; Takaku T; Sato E; Sugimoto KJ; Nakazato T; Fujita H; Kimura Y; Fujioka I; Komatsu N; Asou N; Kizaki M; Hatta Y; Kawaguchi T
Oncol Rep; 2019 Dec; 42(6):2836-2843. PubMed ID: 31578586
[TBL] [Abstract][Full Text] [Related]
49. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
50. Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies.
Hewison A; Atkin K; McCaughan D; Roman E; Smith A; Smith G; Howell D
Eur J Oncol Nurs; 2020 Apr; 45():101730. PubMed ID: 32169687
[TBL] [Abstract][Full Text] [Related]
51. Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Efficace F; Vignetti M; Sparano F; Scalzulli E; Breccia M
Expert Rev Hematol; 2021 Mar; 14(3):293-302. PubMed ID: 33554672
[No Abstract] [Full Text] [Related]
52. Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors.
Hefner J; Csef EJ; Kunzmann V
Oncol Nurs Forum; 2016 Mar; 43(2):190-7. PubMed ID: 26906130
[TBL] [Abstract][Full Text] [Related]
53. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.
Gater A; Heron L; Abetz-Webb L; Coombs J; Simmons J; Guilhot F; Rea D
Leuk Res; 2012 Jul; 36(7):817-25. PubMed ID: 22364811
[TBL] [Abstract][Full Text] [Related]
54. A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.
Rohon P; Faber E; Divoka M; Rozmanova S; Friedecky D; Jarosova M; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Jun; 157(2):181-8. PubMed ID: 22660209
[TBL] [Abstract][Full Text] [Related]
55. Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia.
Clark SE; Marcum ZA; Radich JP; Bansal A
J Oncol Pharm Pract; 2021 Dec; 27(8):1842-1852. PubMed ID: 33175653
[TBL] [Abstract][Full Text] [Related]
56. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
[TBL] [Abstract][Full Text] [Related]
57. Patient perceptions of treatment-free remission in chronic myeloid leukemia.
Villemagne Sanchez LA; O'Callaghan C; Gough K; Hall K; Kashima Y; Seymour JF; Schofield P; Ross DM
Leuk Lymphoma; 2018 Feb; 59(2):406-415. PubMed ID: 28617066
[TBL] [Abstract][Full Text] [Related]
58. Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.
Jönsson S; Olsson B; Söderberg J; Wadenvik H
Ann Hematol; 2012 May; 91(5):679-685. PubMed ID: 22048790
[TBL] [Abstract][Full Text] [Related]
59. Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients.
McMullan RR; McConville C; McMullin MF
Ulster Med J; 2019 May; 88(2):105-110. PubMed ID: 31061559
[TBL] [Abstract][Full Text] [Related]
60. Acceptability of pharmacist-led interventions to resolve drug-related problems in patients with chronic myeloid leukaemia.
Tan BK; Chua SS; Chen LC; Chang KM; Balashanker S; Bee PC
J Oncol Pharm Pract; 2021 Oct; 27(7):1644-1656. PubMed ID: 33040675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]